Biologics such as antibodies are widely favoured in drug discovery due to their inherent potential for specificity to a single target antigen. Despite this, off-target mediated toxicity could present an issue for a subset of antibodies and other molecules in development. Download our PEGS 2017 poster to learn how the Retrogenix human cell microarray technology approach is being applied to identify specific and relevant off-targets with a very low rate of false positive results.
Download our receptor identification and off-target profiling flyer for an overview of the applications of the Retrogenix cell microarray technology.
Further details of how the technology is currently being used by industry and academia can be found by browsing the ‘recent publications’ section of the website.
Download our SOT 2017 poster describing the how the Retrogenix human cell microarray technology has been optimised to screen whole CAR T cells for specific interactions, reducing the risk of unanticipated off-target adverse effects in the development of novel immunotherapies and providing essential supporting data for pre-IND safety assessment.
Download a recent poster presented at PEGS Boston to see some typical results from a cell microarray screen and learn how the Retrogenix technology can assist with immune checkpoint pairing.
Further examples of the applications of the cell microarray technology can also be found in the case studies resource on this website.